Cytokine production by islets in health and diabetes: Cellular origin, regulation and function

Trends in Endocrinology and Metabolism

Volumn 21, Issue 5, 2010, Pages 261-267

  Donath, Marc Y ^a   Böni Schnetzler, Marianne ^a   Ellingsgaard, Helga ^a   Halban, Philippe A ^b   Ehses, Jan A ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INSULIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; THIOREDOXIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; GENE EXPRESSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; MACROPHAGE; METABOLIC STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; CYTOKINES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; INTERLEUKIN-6; ISLETS OF LANGERHANS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77952488104     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.12.010     Document Type: Review

References (93)

1. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
2. Hoffmann A., et al. The Ikappa B-NF-kappa B signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
3. Nelson D.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004, 306:704-708.
4. Jiang B., et al. Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression. J. Biol. Chem. 2004, 279:1323-1329.
5. Spinas G.A., et al. The bimodal effect of interleukin 1 on rat pancreatic beta-cells - stimulation followed by inhibition - depends upon dose, duration of exposure, and ambient glucose concentration. Acta Endocrinol. 1988, 119:307-311.
6. Maedler K., et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006, 55:2713-2722.
7. Ortis F., et al. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol. Endocrinol. 2006, 20:1867-1879.
8. Ehses J.A., et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007, 56:2356-2370.
9. Weksler-Zangen S., et al. Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes 2008, 57:279-287.
10. Arnush M., et al. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J. Immunol. 1998, 160:2684-2691.
11. Heitmeier M.R., et al. Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-kappaB activation. J. Biol. Chem. 1998, 273:15301-15307.
12. Cardozo A.K., et al. Identification of novel cytokine-induced genes in pancreatic beta-cells by high-density oligonucleotide arrays. Diabetes 2001, 50:909-920.
13. Cardozo A.K., et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J. Biol. Chem. 2001, 276:48879-48886.
14. Jacobsen M.L., et al. IL-1beta-induced chemokine and Fas expression are inhibited by suppressor of cytokine signalling-3 in insulin-producing cells. Diabetologia 2009, 52:281-288.
15. Maedler K., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
16. Ribaux P., et al. Induction of CXCL1 by extracellular matrix and autocrine enhancement by interleukin-1 in rat pancreatic beta-cells. Endocrinology 2007, 148:5582-5590.
17. Boni-Schnetzler M., et al. Increased interleukin (IL)-1{beta} messenger ribonucleic acid expression in {beta}-cells of individuals with type 2 diabetes and regulation of IL-1{beta} in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 2008, 93:4065-4074.
18. Matsuda T., et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am. J. Transplant. 2005, 5:484-493.
19. Movahedi B., et al. Pancreatic duct cells in human islet cell preparations are a source of angiogenic cytokines interleukin-8 and vascular endothelial growth factor. Diabetes 2008, 57:2128-2136.
20. Movahedi B., et al. Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004, 47:998-1008.
21. Donath M.Y., et al. Mechanisms of {beta}-cell death in type 2 diabetes. Diabetes 2005, 54(Suppl. 2):S108-S113.
22. Donath M.Y., et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008, 31(Suppl. 2):S161-S164.
23. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996, 39:1005-1029.
24. Stephens L.A., et al. Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. Endocrinology 1999, 140:3219-3227.
25. Flodstrom M., et al. Cytokines activate the nuclear factor kappa B (NF-kappa B) and induce nitric oxide production in human pancreatic islets. FEBS Lett. 1996, 385:4-6.
26. Chang I., et al. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes 2003, 52:1169-1175.
27. Kim S., et al. NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1913-1918.
28. Norlin S., et al. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 2005, 54:125-132.
29. Bernal-Mizrachi E., et al. Activation of nuclear factor-kappaB by depolarization and Ca(2+) influx in MIN6 insulinoma cells. Diabetes 2002, 51:S484-S488.
30. Hammar E., et al. Extracellular matrix protects pancreatic beta-cells against apoptosis: role of short- and long-term signaling pathways. Diabetes 2004, 53:2034-2041.
31. Hammar E.B., et al. Activation of NF-{kappa}B by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. J. Biol. Chem. 2005, 280:30630-30637.
32. Parnaud G., et al. Signaling pathways implicated in the stimulation of beta-cell proliferation by extracellular matrix. Mol. Endocrinol. 2009, 23:1264-1271.
33. Bendtzen K., et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986, 232:1545-1547.
34. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
35. Rhodes C.J. Type 2 diabetes - a matter of beta-cell life and death?. Science 2005, 307:380-384.
36. Robertson R.P., et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl. 1):S119-S124.
37. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl. 3):S16-S21.
38. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995, 44:863-870.
39. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46:3-10. (published erratum appears in Diabetes 1997; 46, 536).
40. Weir G.C., et al. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab. Rev. 1986, 2:125-161.
41. Donath M.Y., et al. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999, 48:738-744.
42. Maedler K., et al. Glucose induces beta-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 2001, 50:1683-1690.
43. Boni-Schnetzler M., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
44. Bikopoulos G., et al. Ex vivo transcriptional profiling of human pancreatic islets following chronic exposure to monounsaturated fatty acids. J. Endocrinol. 2008, 196:455-464.
45. Busch A.K., et al. Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic beta-cell function. Diabetes 2002, 51:977-987.
46. Warner S.J., et al. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J. Exp. Med. 1987, 165:1316-1331.
47. Toda Y., et al. Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J. Immunol. 2002, 168:1984-1991.
48. Maedler K., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8138-8143.
49. Lee J.Y., et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001, 276:16683-16689.
50. Lee J.Y., et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 2004, 279:16971-16979.
51. Haversen L., et al. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 2009, 202:382-393.
52. Leahy J.L., et al. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J. Clin. Invest. 1986, 77:908-915.
53. Kilpatrick E.D., Robertson R.P. Differentiation between glucose-induced desensitization of insulin secretion and beta-cell exhaustion in the HIT-T15 cell line. Diabetes 1998, 47:606-611.
54. Vague P., Moulin J.P. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism 1982, 31:139-142.
55. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 2004, 279:42351-42354.
56. Chen J., et al. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008, 57:938-944.
57. Zhou, R. et al. (in press) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2009 [Epub ahead of print].
58. Ehses J.A., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13998-14003.
59. Cardozo A.K., et al. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003, 46:255-266.
60. Homo-Delarche F., et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006, 55:1625-1633.
61. Li X., et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006, 55:2965-2973.
62. Marselli L., et al. Evidence of inflammatory markers in beta cells of type 2 diabetic subjects. Diabetologia 2007, 50:S178-S179.
63. Pickup J.C., et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
64. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
65. Ehses J.A., et al. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch. Physiol. Biochem. 2009, 115:240-247.
66. Donath M.Y., et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008, 31(Suppl. 2):S161-S164.
67. Weisberg S.P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
68. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
69. Varma V., et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1300-E1310.
70. Richardson S.J., et al. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009, 52:1686-1688.
71. Lacraz G., et al. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS One 2009, 4:e6963.
72. Dinarello C.A. Interleukin-1beta and the autoinflammatory diseases. N. Engl. J. Med. 2009, 360:2467-2470.
73. Herder C., et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005, 54(Suppl. 2):S11-S17.
74. Spranger J., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
75. Kamimura D., et al. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149:1-38.
76. Rabinovitch A., Suarez-Pinzon W.L. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev. Endocr. Metab. Disord. 2003, 4:291-299.
77. Campbell I.L., et al. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 1991, 87:739-742.
78. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(Suppl. 2):S114-S124.
79. Ellingsgaard H., et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13163-13168.
80. Choi S.E., et al. IL-6 protects pancreatic islet beta cells from proinflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl. Immunol. 2004, 13:43-53.
81. Campbell I.L., et al. Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am. J. Pathol. 1994, 145:157-166.
82. Gromada J., et al. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 2007, 28:84-116.
83. Guardado-Mendoza R., et al. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13992-13997.
84. Wideman R.D., et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13468-13473.
85. Gelling R.W., et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E695-E707.
86. Febbraio M.A., Pedersen B.K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002, 16:1335-1347.
87. Donath M.Y., et al. XOMA 052, an anti-IL-1beta antibody, in a double-blind, placebo-controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus - a new approach to therapy. Diabetologia 2008, 51:S7.
88. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
89. Larsen C.M., et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009, 32:1663-1668.
90. Shoelson S. Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J. Mol. Med. 2002, 80:618-619.
91. Shoelson S.E., Goldfine A.B. Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat. Med. 2009, 15:373-374.
92. Shoelson S.E., et al. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 2003, 27(Suppl. 3):S49-S52.
93. Ridker P.M., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207.